REGN as reported
Regeneron Pharmaceuticals reported $15.5B of revenue over the trailing twelve months, +9.3% on the year before. 11 reported series are charted on this page, each one as filed.
$15.5B
Revenue, trailing twelve months · to Q2 2026 · +9.3% against the twelve months before
- Net Income
- $4.33B
Net Income · −2.9% year on year · trailing twelve months to Q2 2026
- Free Cash Flow
- $3.76B
Free Cash Flow · −2.4% year on year · trailing twelve months to Q2 2026
- Op Margin
- 24%
Op Margin · trailing twelve months to Q2 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Revenue | $15.5B | +9.3% | Q2 2026 |
| Net Income | $4.33B | −2.9% | Q2 2026 |
| EPS | $40.47 | +1.9% | Q2 2026 |
| Gross Margin | 97% | n/a | Q1 2018 · 33 quarters behind |
| Op Margin | 24% | n/a | Q2 2026 |
| Net Margin | 28% | n/a | Q2 2026 |
| ROE | 14% | n/a | Q2 2026 |
| ROA | 11% | n/a | Q2 2026 |
| ROIC | 12% | n/a | Q2 2026 |
| Free Cash Flow | $3.76B | −2.4% | Q2 2026 |
| P/E | 20.1 | n/a | today |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
Regeneron Pharmaceuticals (REGN) - Revenue & ProfitRevenue & ProfitRegeneron Pharmaceuticals (REGN)
Revenue (TTM)Net Income (TTM)
Powered byryufin.com